Cirtuvivint for advanced soft-tissue sarcomas
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called Cirtuvivint for people with certain advanced soft-tissue sarcomas that have grown recently. It aims to see if the drug can stop or slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 70 years old.
- You have one of these sarcoma types: solitary fibrous tumor, synovial sarcoma, clear cell sarcoma, extraskeletal myxoid chondrosarcoma, alveolar soft part sarcoma, myxoid liposarcoma, or desmoid tumor.
- Your sarcoma has grown or spread in the last 6 months.
- You have had at least one type of chemotherapy (anthracyclines) before, unless you have solitary fibrous tumor.
- You are willing to provide a tumor sample and blood samples for study purposes.
- You have a good performance status (ECOG 0-1) and adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy: an injected virus (OVV-01) alongside an immunotherapy drug (AK112) for people with advanced soft tissue sarcoma that hasn't responded to usual treatments. The aim is to see if this approach can help shrink tumors or slow their growth.
This study tests a combination of two chemotherapy drugs—utidelone and doxorubicin—for people with advanced soft tissue sarcoma. The goal is to see if this combination can help shrink or slow the cancer.
This trial is testing a new combination of four treatments (an experimental drug, two chemo-like drugs, and radiation) for advanced soft tissue sarcoma that hasn't responded to earlier treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial combines cryoablation (a freezing technique to destroy tumors) with camrelizumab (an immunotherapy drug that helps your immune system fight cancer) for patients with advanced soft tissue sarcoma that hasn't responded to standard treatments. The goal is to see if this combination works better than current options.
This trial tests a new way of giving radiation therapy (called spatially fractionated radiotherapy) combined with a treatment strategy called PraG (pembrolizumab and granulocyte-macrophage colony-stimulating factor) for people with soft tissue sarcoma that cannot be removed or has spread. The goal is to see if the combination can help shrink or control the cancer.
This trial tests a new drug, HS-20093, combined with other treatments for people with advanced bone or soft tissue sarcoma. The goal is to see if these combinations can shrink tumors or slow their growth.
Hear when a new Soft Tissue Sarcoma (STS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.